Sarcopenia – Epidemiology – Epidemiology – Sarcopenia – Mature markets

Clarivate Epidemiology’s coverage of sarcopenia comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the total prevalence of sarcopenia for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s sarcopenia forecast will answer the following questions:

• How will changes in the levels of exposure to known risk or protective factors affect the number of people with sarcopenia per year?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of sarcopenia over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts the following sarcopenia populations:

• Total prevalent cases of European Working Group on Sarcopenia in Older People 2 (EWGSOP2) / Asian Working Group for Sarcopenia 2 (AWGS2)¹ sarcopenia.
• Total prevalent cases of severe EWGSOP2/AWGS2 sarcopenia.
• Total prevalent cases of non-severe EWGSOP2/AWGS2 sarcopenia.
• Total prevalent cases of EWGSOP1/AWGS1 sarcopenia.

¹The EWGSOP2 (Cruz-Jentoft AJ, 2019) and AWGS2 (Chen LK, 2020) diagnostic criteria are based on similar frameworks but focus on European and Asian populations, respectively; EWGSOP1 (Cruz-Jentoft AJ, 2010) and AWGS1 (Chen LK, 2014) are their previous versions.

Note: Coverage may vary by country.